Skip to main content
Premium Trial:

Request an Annual Quote

JPT Technologies Adopts Arrayjet Arrayer for Peptide Chip Production

Premium

Arrayjet recently installed a customized version of its Ultra Marathon microarrayer instrument at JPT Technologies.

Berlin-based JPT, a subsidiary of BioNTech, will use the Ultra Marathon to print its PepStar peptide microarrays for use in vaccine and immunotherapy development, as well as diagnostics, according to CEO Holger Wenschuh.

Wenshuh said in a statement that the company acquired the high-throughput arrayer, which is capable of printing up to 1,000 slides in a single run, to "comply with large immune monitoring and biomarker discovery projects." He added that the custom instrument meets the "specific challenges of our regulated production environment."

Based in Edinburgh, UK, Arrayjet offers a line of arrayers and services based on its inkjet array printing technology. JPT offers a number of peptide-related services and tools, including high-throughput peptide synthesis and screening, arrays, library assembly, antigen-specific T-cell stimulation, and protein biomarker quantification.

Further details of the deal were not discussed.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.